RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

NCT05417230 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: RC48-ADC
DRUG: Envafolimab

Sponsor

Jiangsu Cancer Institute & Hospital